All In Biotech

Drug Trial Radar · NCT04763759

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

A Phase 1, Blinded, Single Ascending Dose Study to Evaluate Safety, Pharmacokinetics, and Activity of TRL1068 in Subjects With Prosthetic Joint Infection of the Knee or Hip, Undergoing Primary Two Stage Exchange Arthroplasty

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Feb 8, 2021

Primary completion

Mar 13, 2024

Study completion Mar 13, 2024

Sponsor

Lead sponsor
Trellis Bioscience LLCIndustry
Sponsor type
Industry
Collaborators
University of California, Los Angeles; Biomedical Advanced Research and Development Authority; Wellcome Trust; Sinai Hospital of Baltimore; Gulfcoast Research Institute; Phoenix Clinical Research; University of Florida; University of Alabama at Birmingham; The Methodist Hospital Research Institute; University of Virginia; University of Southern California
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.

Conditions

  • Prosthetic Joint Infection

Interventions

  • TRL1068, a human monoclonal antibodyDrug

    A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Abnormal Physical Examination FindingsTime frame: 16 weeks
  2. Incidence of Abnormal Serum Chemistries and HematologyTime frame: 16 weeks
  3. Incidence of Abnormal Vital Signs (Temperature)Time frame: 16 weeks
  4. Incidence of Abnormal Vital Signs (Blood Pressure)Time frame: 16 weeks
  5. Incidence of Abnormal Vital Signs (Heart Rate)Time frame: 16 weeks
  6. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 24 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • USC

    Los Angeles, California

  • UCLA

    Santa Monica, California

  • University of Florida

    Gainesville, Florida

  • Gulfcoast Research Institute

    Sarasota, Florida

  • Phoenix Clinical Research

    Tamarac, Florida

  • Sinai Hospital of Baltimore

    Baltimore, Maryland

  • Houston Methodist Research Institute

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.